More analyst madness about Transmeta

IF YOU THINK that analysts are very very strange folks, carry on reading. Otherwise, please leave this story immediately. You're not allowed to read it.

Transmeta's share price is over $4, but fell because it missed its own estimate by nearly 50%.

Hans Mossemann, who used to be a wiseacre at a big firm in Wall Street, now runs his own research firm called Semiconductor Research.

He said that while TMTA missed its $5.1 million revenue assumption for the third quarter by a wide margin, its aging Crusoe architecture is to blame, not his analysis.

He said that the Efficeon will gain mainstream presence in the notebook space. He said weakness in the shares is a great opportunity for investors who want to make money over the next two years.

TMTA is likely to make big design wins.

Look, just read the INQUIRER. You know it makes sense. It's high time Nvidia buys TMTA.